CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 485 enrolled
Drug / intervention
Eptinezumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04152083
NCT04152083Phase 3Completed
CompareCT.gov

A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine

H. Lundbeck A/S·interventional·Posted Nov 5, 2019·Updated Aug 17, 2021

In Brief

A Phase 3 clinical trial evaluating Eptinezumab and Placebo for Migraine. Completed, enrolled 485 participants across 57 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of eptinezumab administered intravenously in participants experiencing an acute attack of migraine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesGeorgia, United States
CollaboratorsAlder Biopharmaceuticals, Inc.

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedNov 5, 2019
Enrollment StartNov 7, 2019
Primary CompletionJul 8, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.7 years ago

Interventions

Eptinezumabdrug

Injection for IV administration

Placebodrug

Injection for IV administration